Emergent BioSolutions Inc
NYSE:EBS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Ramsay Generale de Sante SA
XBER:GD6
|
FR |
|
Turk Hava Yollari AO
OTC:TKHVY
|
TR |
Emergent BioSolutions Inc
Research & Development
Emergent BioSolutions Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Emergent BioSolutions Inc
NYSE:EBS
|
Research & Development
-$53.2m
|
CAGR 3-Years
34%
|
CAGR 5-Years
24%
|
CAGR 10-Years
8%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Research & Development
-$523m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-31%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
Emergent BioSolutions Inc
Glance View
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,416 full-time employees. The company went IPO on 2006-11-15. The firm is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. The company provides solutions for public health threats through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. The firm also offers a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers.
See Also
What is Emergent BioSolutions Inc's Research & Development?
Research & Development
-53.2m
USD
Based on the financial report for Dec 31, 2025, Emergent BioSolutions Inc's Research & Development amounts to -53.2m USD.
What is Emergent BioSolutions Inc's Research & Development growth rate?
Research & Development CAGR 10Y
8%
Over the last year, the Research & Development growth was 25%. The average annual Research & Development growth rates for Emergent BioSolutions Inc have been 34% over the past three years , 24% over the past five years , and 8% over the past ten years .
